User profiles for I. C. Smith

Ian Smith

- Verified email at hw.ac.uk - Cited by 56901

Ian C Smith

- Verified email at lilly.com - Cited by 9628

Ian Smith

- Verified email at gene.com - Cited by 9498

[HTML][HTML] Obesity, metabolic syndrome, and musculoskeletal disease: common inflammatory pathways suggest a central role for loss of muscle integrity

…, GZ MacDonald, RA Reimer, JL Rios, IC Smith… - Frontiers in …, 2018 - frontiersin.org
Inflammation can arise in response to a variety of stimuli, including infectious agents, tissue
injury, autoimmune diseases, and obesity. Some of these responses are acute and resolve, …

A systematic review of sensory-based treatments for children with disabilities

EE Barton, B Reichow, A Schnitz, IC Smith… - Research in …, 2015 - Elsevier
Sensory-based therapies are designed to address sensory processing difficulties by helping
to organize and control the regulation of environmental sensory inputs. These treatments …

Development of a college transition and support program for students with autism spectrum disorder

SW White, R Elias, NN Capriola-Hall, IC Smith… - Journal of autism and …, 2017 - Springer
Empirically based, consumer-informed programming to support students with Autism Spectrum
Disorder (ASD) transitioning to college is needed. Informed by theory and research, the …

[HTML][HTML] A next generation connectivity map: L1000 platform and the first 1,000,000 profiles

…, M Donahue, B Julian, M Khan, D Wadden, IC Smith… - Cell, 2017 - Elsevier
We previously piloted the concept of a Connectivity Map (CMap), whereby genes, drugs, and
disease states are connected by virtue of common gene-expression signatures. Here, we …

A layered hybrid perovskite solar‐cell absorber with enhanced moisture stability

IC Smith, ET Hoke, D Solis‐Ibarra… - Angewandte Chemie …, 2014 - Wiley Online Library
Two‐dimensional hybrid perovskites are used as absorbers in solar cells. Our first‐generation
devices containing (PEA) 2 (MA) 2 [Pb 3 I 10 ] (1; PEA=C 6 H 5 (CH 2 ) 2 NH 3 + , MA=CH …

MONARCH 3: abemaciclib as initial therapy for advanced breast cancer

…, T Forrester, M Frenzel, S Barriga, IC Smith… - Journal of Clinical …, 2017 - ascopubs.org
Purpose Abemaciclib, a cyclin-dependent kinase 4 and 6 inhibitor, demonstrated efficacy as
monotherapy and in combination with fulvestrant in women with hormone receptor (HR)–…

MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2− advanced breast cancer who had progressed while receiving endocrine therapy

…, M Frenzel, Y Lin, S Barriga, IC Smith… - Journal of clinical …, 2017 - ascopubs.org
Purpose MONARCH 2 ( ClinicalTrials.gov identifier: NCT02107703) compared the efficacy
and safety of abemaciclib, a selective cyclin-dependent kinase 4 and 6 inhibitor, plus …

Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel

IC Smith, SD Heys, AW Hutcheon, ID Miller… - Journal of clinical …, 2002 - ascopubs.org
PURPOSE: To compare the efficacy of neoadjuvant (NA) docetaxel (DOC) with anthracycline-based
therapy and determine the efficacy of NA DOC in patients with breast cancer initially …

Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2−, node-positive, high-risk, early breast cancer (monarchE)

…, A Wardley, SM Tolaney, I Cicin, IC Smith… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE Many patients with HR+, HER2− early breast cancer (EBC) will not experience
recurrence or have distant recurrence with currently available standard therapies. However, …

Positron Emission Tomography Using [18F]-Fluorodeoxy-d-Glucose to Predict the Pathologic Response of Breast Cancer to Primary Chemotherapy

IC Smith, AE Welch, AW Hutcheon, ID Miller… - Journal of Clinical …, 2000 - ascopubs.org
PURPOSE: To determine whether [ 18 F]-fluorodeoxy-d-glucose ([ 18 F]-FDG) positron emission
tomography (PET) can predict the pathologic response of primary and metastatic breast …